Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study

#1284

Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.

Aim(s): To evaluate PK of LD SQ vs IM.

Materials and methods: In a phase I study, healthy adult volunteers received 1 mg LD (IV bolus) followed by 60 mg 0.246 mg/mg deep SC or IM. Serial blood samples were analyzed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Manon A

Authors: Manon A, Wolin E, Chassaing C, Lewis A, Bertocchi L,

Keywords: lanreotide, Somatuline, pharmacokinetic, PK,